CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...